-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Vorinostat
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/149647-78-9.gif)
| Category | Human papillomavirus (HPV) |
| CAS | 149647-78-9 |
| Description | Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM. |
Product Information
| Synonyms | MK-0683, MK 0683, MK0683, SAHA, M344, CCRIS 8456, HSDB 7930, Vorinostat, suberoylanilide hydroxamic acid, Zolinza |
| IUPAC Name | N'-hydroxy-N-phenyloctanediamide |
| Molecular Weight | 264.3 |
| Molecular Formula | C14H20N2O3 |
| Canonical SMILES | C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO |
| InChI | InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18) |
| InChIKey | WAEXFXRVDQXREF-UHFFFAOYSA-N |
| Melting Point | 161-164 °C |
| Purity | >98% |
| Density | 1.174 g/cm³ |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | White Solid |
| Application | Antineoplastic agents; histone deacetylase inhibitors |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 276 |
| Exact Mass | 264.14739250 |
| Index Of Refraction | 1.567 |
| In Vitro | Vorinostat efficiently suppresses MES-SA cell growth at a low dosage (3 μM) already after 24 hours treatment. HDACs class I (HDAC2 and 3) as well as class II (HDAC7) are preferentially affected by this treatment. Vorinostat significantly increases p21WAF1 expression and Apoptosis in MES-SA cells. Vorinostat inhibits SK-N-SH and SK-N-Be(2)C with the IC25 values of 1 µM and 0.5 µM, respectively. Vorinostat is an effective inhibitor of HPV-18 DNA amplification, reduces oncoproteins E6 and E7 activities and triggers Apoptosis in HPV-infected, differentiated cells. |
| In Vivo | Vorinostat (50 mg/kg/day) reduces tumor growth by more than 50% in nude mice injected with 5×106 MES-SA cells. |
| PSA | 78.43 |
| Target | HDAC; Autophagy; Mitophagy; Filovirus; Apoptosis; HPV |
| XLogP3-AA | 1.9 |
